These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 16135655)

  • 21. Olanzapine treatment and weight gain: considering the lipid side effects of antipsychotics.
    Balf G
    Am J Psychiatry; 2008 Sep; 165(9):1206-7; author reply 1207. PubMed ID: 18765500
    [No Abstract]   [Full Text] [Related]  

  • 22. Newer antipsychotic drugs and obesity in children and adolescents. How should we assess drug-associated weight gain?
    Vieweg WV; Sood AB; Pandurangi A; Silverman JJ
    Acta Psychiatr Scand; 2005 Mar; 111(3):177-84. PubMed ID: 15701101
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pilot study of the G-protein beta3 subunit gene (C825T) polymorphism and clinical response to olanzapine or olanzapine-related weight gain in persons with schizophrenia.
    Bishop JR; Ellingrod VL; Moline J; Miller D
    Med Sci Monit; 2006 Feb; 12(2):BR47-50. PubMed ID: 16449941
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polymorphisms of the histamine receptor (H1HR) gene are not associated with olanzapine-induced weight gain.
    Godlewska BR; Olajossy-Hilkesberger L; Olajossy M; Limon J; Landowski J
    J Clin Psychopharmacol; 2013 Jun; 33(3):436-7. PubMed ID: 23609395
    [No Abstract]   [Full Text] [Related]  

  • 25. Dyslipidemia and atypical antipsychotic drugs.
    Casey DE
    J Clin Psychiatry; 2004; 65 Suppl 18():27-35. PubMed ID: 15600382
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Body weight gain induced by a newer antipsychotic agent reversed as negative symptoms improved.
    Koga M; Nakayama K
    Acta Psychiatr Scand; 2005 Jul; 112(1):75-6; discussion 77. PubMed ID: 15952949
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis.
    Graham KA; Perkins DO; Edwards LJ; Barrier RC; Lieberman JA; Harp JB
    Am J Psychiatry; 2005 Jan; 162(1):118-23. PubMed ID: 15625209
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modelling olanzapine-induced weight gain in rats.
    van der Zwaal EM; Janhunen SK; la Fleur SE; Adan RA
    Int J Neuropsychopharmacol; 2014 Jan; 17(1):169-86. PubMed ID: 24103788
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term treatment with atypical antipsychotics and risk of weight gain.
    Stip E; Anselmo K; Wolfe M; Lessard C; Landry P
    Drug Saf; 2006; 29(6):550-2; author reply 552. PubMed ID: 16752937
    [No Abstract]   [Full Text] [Related]  

  • 30. [Expectations and developments in atypical antipsychotics].
    Praxis (Bern 1994); 2004 Aug; 93(35):1392. PubMed ID: 15468579
    [No Abstract]   [Full Text] [Related]  

  • 31. Weight gain associated with antipsychotic drugs.
    Ganguli R
    J Clin Psychiatry; 1999; 60 Suppl 21():20-4. PubMed ID: 10548138
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Meralgia paresthetica: another complication of antipsychotic-induced weight gain.
    Chlebowski S; Bashyal S; Schwartz TL
    Obes Rev; 2009 Nov; 10(6):700-2. PubMed ID: 19413704
    [No Abstract]   [Full Text] [Related]  

  • 33. Comments on "Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine".
    Reis de Sá A; Elkis H
    Braz J Psychiatry; 2007 Mar; 29(1):90; author reply 91. PubMed ID: 17435940
    [No Abstract]   [Full Text] [Related]  

  • 34. A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia.
    Kim JH; Yim SJ; Nam JH
    Schizophr Res; 2006 Feb; 82(1):115-7. PubMed ID: 16326074
    [No Abstract]   [Full Text] [Related]  

  • 35. Insulin resistance index and counter-regulatory factors during olanzapine or risperidone administration in subjects with schizophrenia.
    Baptista T; Martinez M; Lacruz A; Arellano A; Mendoza S; Beaulieu S; Hernández L; Contreras Q; Galeazzi T; Vargas D
    Schizophr Res; 2007 Jan; 89(1-3):350-2. PubMed ID: 17029751
    [No Abstract]   [Full Text] [Related]  

  • 36. Plasma nitric oxide and leptin values in patients with olanzapine-induced weight gain.
    Atmaca M; Tezcan E; Ustundag B
    J Psychiatr Res; 2007; 41(1-2):74-9. PubMed ID: 16426639
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interventions to reduce weight gain in schizophrenia.
    Faulkner G; Cohn T; Remington G
    Schizophr Bull; 2007 May; 33(3):654-6. PubMed ID: 17449900
    [No Abstract]   [Full Text] [Related]  

  • 38. Cognitive behavior therapy for weight gain.
    Umbricht D; Flury H; Bridler R
    Am J Psychiatry; 2001 Jun; 158(6):971. PubMed ID: 11384925
    [No Abstract]   [Full Text] [Related]  

  • 39. Olanzapine treatment of eight adolescent patients with psychosis.
    Ercan ES; Kutlu A; Varan A; Cikoğlu S; Coşkunol H; Bayraktar E
    Hum Psychopharmacol; 2004 Jan; 19(1):53-6. PubMed ID: 14716713
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unusual suspect for antipsychotic-induced diabetes.
    O'Neill MF
    Drug Discov Today; 2005 Oct; 10(20):1338. PubMed ID: 16253867
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.